Prevalence rates (%) of antiretroviral drugs.
- Jurgen Vercauteren (364296)
- Gertjan Beheydt (403788)
- Mattia Prosperi (132270)
- Pieter Libin (308222)
- Stijn Imbrechts (403789)
- Ricardo Camacho (7890)
- Bonaventura Clotet (91238)
- Andrea De Luca (132288)
- Zehava Grossman (7882)
- Rolf Kaiser (238438)
- Anders Sönnerborg (153581)
- Carlo Torti (237805)
- Eric Van Wijngaerden (403790)
- Jean-Claude Schmit (80737)
- Maurizio Zazzi (146810)
- Anna-Maria Geretti (225525)
- Anne-Mieke Vandamme (7884)
- Kristel Van Laethem (80734)
Publication date
April 2013
DOIAbstract
<p>Nucleotide/side reverse transcriptase inhibitors (N(t)RTIs): lamivudine (3TC), tenofovir (TDF), zidovudine (AZT), emtricitabine (FTC), didanosine (DDI), abacavir (ABC), stavudine (D4T), zalcitabine (DDC); non-nucleoside reverse transcriptase inhibitors (NNRTIs): efavirenz (EFV), nevirapine (NVP), etravirine (ETR); protease inhibitors (PIs): lopinavir (LPV/r), atazanavir (ATV), nelfinavir (NFV), saquinavir (SQV), indinavir (IDV), fosamprenavir (FPV), darunavir (DRV), amprenavir (APV), tipranavir (TPV), along with boosting ritonavir (RTV).</p
Add to ORKG